Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $18.36 in the prior trading day, Bicara Therapeutics Inc (NASDAQ: BCAX) closed at $18.15, down -1.14%. In other words, the price has decreased by -$1.14 from its previous closing price. On the day, 0.56 million shares were traded. BCAX stock price reached its highest trading level at $18.73 during the session, while it also had its lowest trading level at $17.63.
Ratios:
Our goal is to gain a better understanding of BCAX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.14 and its Current Ratio is at 14.14. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $36.
On May 23, 2025, Wells Fargo Upgraded its rating to Equal Weight which previously was Underweight but kept the price unchanged to $8.
On April 17, 2025, Wells Fargo started tracking the stock assigning a Underweight rating and target price of $8.Wells Fargo initiated its Underweight rating on April 17, 2025, with a $8 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 15 ’25 when Cohlhepp Ryan sold 12,500 shares for $18.68 per share. The transaction valued at 233,548 led to the insider holds 189,141 shares of the business.
Cohlhepp Ryan bought 12,500 shares of BCAX for $233,750 on Dec 15 ’25. On Nov 24 ’25, another insider, Hyep Ivan, who serves as the Chief Financial Officer of the company, sold 17,795 shares for $18.55 each. As a result, the insider received 330,094 and left with 145,355 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCAX now has a Market Capitalization of 994292416 and an Enterprise Value of 706100416.
Stock Price History:
The Beta on a monthly basis for BCAX is -0.84, which has changed by 0.12362301 over the last 52 weeks, in comparison to a change of 0.16081822 over the same period for the S&P500. Over the past 52 weeks, BCAX has reached a high of $19.75, while it has fallen to a 52-week low of $7.80. The 50-Day Moving Average of the stock is 6.51%, while the 200-Day Moving Average is calculated to be 37.00%.
Shares Statistics:
The stock has traded on average 715.32K shares per day over the past 3-months and 669570 shares per day over the last 10 days, according to various share statistics. A total of 54.61M shares are outstanding, with a floating share count of 32.06M. Insiders hold about 41.47% of the company’s shares, while institutions hold 63.95% stake in the company. Shares short for BCAX as of 1764288000 were 7655080 with a Short Ratio of 10.70, compared to 1761868800 on 6457982. Therefore, it implies a Short% of Shares Outstanding of 7655080 and a Short% of Float of 21.82.
Earnings Estimates
Currently, 7.0 analysts are dedicated to thoroughly evaluating and rating the performance of Bicara Therapeutics Inc (BCAX) in the stock market.The consensus estimate for the next quarter is -$0.7, with high estimates of -$0.58 and low estimates of -$0.79.
Analysts are recommending an EPS of between -$2.34 and -$2.58 for the fiscal current year, implying an average EPS of -$2.49. EPS for the following year is -$2.95, with 7.0 analysts recommending between -$2.31 and -$3.4.
